{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T16:00:02Z","timestamp":1774368002843,"version":"3.50.1"},"reference-count":59,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2025,3,7]],"date-time":"2025-03-07T00:00:00Z","timestamp":1741305600000},"content-version":"vor","delay-in-days":6,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Cancer Medicine"],"published-print":{"date-parts":[[2025,3]]},"abstract":"<jats:title>ABSTRACT<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>There is a lack of clear guidance on the appropriate next choice of therapy for patients with relapsed\/refractory multiple myeloma who become refractory to daratumumab, an anti\u2010CD38 antibody. This review aims to identify and compare treatments with published clinical trial evidence among patients with daratumumab\u2010refractory multiple myeloma.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>MEDLINE, Cochrane CENTRAL, and EMBASE databases were searched for clinical trials that evaluated treatments for patients with multiple myeloma who were refractory to daratumumab from November 2015 to October 2023. Eligible studies may have enrolled only patients who were refractory to daratumumab or reported findings on patients with daratumumab\u2010refractory disease in subgroup analyses. Treatment outcomes of interest included response rates and survival outcomes. Screening and data extraction were done independently by two reviewers using covidence, and any discrepancy was resolved by a third reviewer. Qualitative synthesis was performed to describe and compare patient outcomes associated with different treatments.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>A total of 33 papers\/published studies, representing 23 clinical trials, were eligible\/included. Interventions from the eligible trials include chimeric antigen receptor (CAR)\u2010T cell therapy, B\u2010cell maturation antigen (BCMA)\u2010directed antibodies, other monoclonal antibodies, cereblon E3 ligase modulators, a peptide\u2010drug conjugate, and other targeted therapies. CAR T\u2010cell therapy demonstrated the highest overall response rates, longer median overall, and progression\u2010free survival in addition to significantly lower risk of death and higher odds of response compared to standard of care. Similarly, high response rates and\/or long\u2010term survival was also observed for other BCMA\u2010directed treatments, such as elranatamab and teclistamab.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Based on the results of this systematic review, BCMA\u2010directed therapies such as CAR\u2010T cell therapy and bispecific antibodies demonstrate promising efficacy among patients with anti\u2010CD38 refractory disease. However, additional evidence from randomized clinical trials is necessary to establish best practice guidelines.<\/jats:p><\/jats:sec>","DOI":"10.1002\/cam4.70585","type":"journal-article","created":{"date-parts":[[2025,3,11]],"date-time":"2025-03-11T22:37:57Z","timestamp":1741732677000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Treatment of Multiple Myeloma in Patients Refractory to Daratumumab\/Anti\u2010CD38 Monoclonal Antibodies: A Systematic Review"],"prefix":"10.1002","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2452-0556","authenticated-orcid":false,"given":"Chia Jie","family":"Tan","sequence":"first","affiliation":[{"name":"Department of Pharmacotherapy, College of Pharmacy University of Utah  Salt Lake City Utah USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dylan","family":"Kacerek","sequence":"additional","affiliation":[{"name":"Department of Pharmacotherapy, College of Pharmacy University of Utah  Salt Lake City Utah USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nattawara","family":"Kampirapawong","sequence":"additional","affiliation":[{"name":"University of Phayao  Phayao Thailand"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amandeep","family":"Godara","sequence":"additional","affiliation":[{"name":"Division of Hematology and Hematologic Malignancies, Huntsman Cancer Institute University of Utah  Salt Lake City Utah USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nathorn","family":"Chaiyakunapruk","sequence":"additional","affiliation":[{"name":"Department of Pharmacotherapy, College of Pharmacy University of Utah  Salt Lake City Utah USA"},{"name":"IDEAS Center, Veterans Affairs Salt Lake City Healthcare System  Salt Lake City Utah USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2025,3,7]]},"reference":[{"key":"e_1_2_9_2_1","volume-title":"Cancer Stat Facts: Myeloma","author":"National Cancer Institute: Surveillance, Epidemiology, and End Results Program","year":"2024"},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.3390\/medsci9010003"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12325\u2010022\u201002083\u20108"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41598\u2010021\u201001440\u2010x"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.15098"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/s0140\u20106736(15)01120\u20104"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1817249"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1714678"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/s1470\u20102045(21)00428\u20109"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/s2352\u20103026(20)30081\u20108"},{"key":"e_1_2_9_12_1","volume-title":"NCCN Clinical Practice Guidelines in Oncology for Multiple Myeloma Version 4.2024","author":"National Comprehensive Cancer Network","year":"2024"},{"key":"e_1_2_9_13_1","unstructured":"J.Higgins J.Thomas J.Chandler et\u00a0al. \u201cCochrane Handbook for Systematic Reviews of Interventions Version 6.4 \u201d2023 training.cochrane.org\/handbook."},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71"},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.1002\/cl2.1230"},{"key":"e_1_2_9_16_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2404284"},{"key":"e_1_2_9_17_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.l4898"},{"key":"e_1_2_9_18_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.i4919"},{"key":"e_1_2_9_19_1","doi-asserted-by":"publisher","DOI":"10.1002\/jrsm.1411"},{"key":"e_1_2_9_20_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2022007210"},{"key":"e_1_2_9_21_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2022.281628"},{"key":"e_1_2_9_22_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41591\u2010022\u201002182\u20107"},{"key":"e_1_2_9_23_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.00842"},{"key":"e_1_2_9_24_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2303379"},{"key":"e_1_2_9_25_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2024850"},{"key":"e_1_2_9_26_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12185\u2010023\u201003538\u20106"},{"key":"e_1_2_9_27_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2213614"},{"key":"e_1_2_9_28_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41408\u2010020\u201000369\u20100"},{"key":"e_1_2_9_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470\u20102045(19)30788\u20100"},{"key":"e_1_2_9_30_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.33809"},{"key":"e_1_2_9_31_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.18720"},{"key":"e_1_2_9_32_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41591\u2010023\u201002528\u20109"},{"key":"e_1_2_9_33_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.01504"},{"key":"e_1_2_9_34_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375\u2010020\u20100834\u20109"},{"key":"e_1_2_9_35_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140\u20106736(21)01338\u20106"},{"key":"e_1_2_9_36_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2203478"},{"key":"e_1_2_9_37_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood\u20102022\u2010164656"},{"key":"e_1_2_9_38_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41408\u2010021\u201000478\u20104"},{"key":"e_1_2_9_39_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375\u2010021\u201001262\u2010w"},{"key":"e_1_2_9_40_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2204591"},{"key":"e_1_2_9_41_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2023.41.16_suppl.8003"},{"key":"e_1_2_9_42_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood\u20102021\u2010147704"},{"key":"e_1_2_9_43_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352\u20103026(22)00290\u20103"},{"key":"e_1_2_9_44_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2303194"},{"key":"e_1_2_9_45_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V128.22.491.491"},{"key":"e_1_2_9_46_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.75.5207"},{"key":"e_1_2_9_47_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1903455"},{"key":"e_1_2_9_48_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.02259"},{"key":"e_1_2_9_49_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood\u20102021\u2010146994"},{"key":"e_1_2_9_50_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41416\u2010021\u201001608\u20102"},{"key":"e_1_2_9_51_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12916\u2010022\u201002305\u20104"},{"key":"e_1_2_9_52_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2020004146"},{"key":"e_1_2_9_53_1","doi-asserted-by":"publisher","DOI":"10.1016\/s2352\u20103026(22)00226\u20105"},{"key":"e_1_2_9_54_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.blre.2023.101136"},{"key":"e_1_2_9_55_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375\u2010020\u20100734\u2010z"},{"key":"e_1_2_9_56_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2024.2396"},{"key":"e_1_2_9_57_1","doi-asserted-by":"publisher","DOI":"10.1200\/op.23.00336"},{"key":"e_1_2_9_58_1","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2023.1271657"},{"key":"e_1_2_9_59_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2401361"},{"key":"e_1_2_9_60_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2023.101158"}],"container-title":["Cancer Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cam4.70585","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,12]],"date-time":"2025-03-12T13:28:18Z","timestamp":1741786098000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/cam4.70585"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3]]},"references-count":59,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,3]]}},"alternative-id":["10.1002\/cam4.70585"],"URL":"https:\/\/doi.org\/10.1002\/cam4.70585","archive":["Portico"],"relation":{},"ISSN":["2045-7634","2045-7634"],"issn-type":[{"value":"2045-7634","type":"print"},{"value":"2045-7634","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3]]},"assertion":[{"value":"2024-11-03","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-12-29","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-03-07","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e70585"}}